Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2021

Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential

(1) , (2) , (3) , (4) , (4) , (4) , (4) , (5) , (2) , (3) , (6) , (4) , (4) , (7) , (4) , (7) , (5) , (1) , (4)
1
2
3
4
5
6
7
Leonard Daly
Marius Walter
Charles Craik
Patrick Eyers
Yann Gambin
Emma Sierecki
Eric Verdin
Edward Emmott
  • Function : Correspondent author
  • PersonId : 1141833

Connectez-vous pour contacter l'auteur

Abstract

Abstract SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, responsible for over 170 million infections, and over 3.7 million deaths worldwide. Efforts to test, treat and vaccinate against this pathogen all benefit from an improved understanding of the basic biology of SARS-CoV-2. Both viral and cellular proteases play a crucial role in SARS-CoV-2 replication. Here, we study proteolytic cleavage of viral and cellular proteins in two cell line models of SARS-CoV-2 replication using mass spectrometry to identify protein neo-N-termini generated through protease activity. We identify previously unknown cleavage sites in multiple viral proteins, including major antigens S and N: the main targets for vaccine and antibody testing efforts. We discover significant increases in cellular cleavage events consistent with cleavage by SARS-CoV-2 main protease, and identify 14 potential high-confidence substrates of the main and papain-like proteases. We show that siRNA depletion of these cellular proteins inhibits SARS-CoV-2 replication, and that drugs targeting two of these proteins: the tyrosine kinase SRC and Ser/Thr kinase MYLK, show a dose-dependent reduction in SARS-CoV-2 titres. Overall, our study provides a powerful resource to understand proteolysis in the context of viral infection, and to inform the development of targeted strategies to inhibit SARS-CoV-2 and treat COVID-19.
Fichier principal
Vignette du fichier
s41467-021-25796-w.pdf (10.85 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03654295 , version 1 (28-04-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Bjoern Meyer, Jeanne Chiaravalli, Stacy Gellenoncourt, Philip Brownridge, Dominic Bryne, et al.. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nature Communications, 2021, 12 (1), pp.5553. ⟨10.1038/s41467-021-25796-w⟩. ⟨pasteur-03654295⟩

Collections

PASTEUR CNRS ANR
4 View
22 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More